MarketCap
Facebook
X
Telegram
Tenax Therapeutics Total Assets | TENX
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Tenax Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 1967 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 104 M | 96.7 M | 11.7 M | 3.4 M | 5.99 M | 6.87 M | 6.37 M | 13.3 M | 9.89 M | 23.3 M | 82.9 M | 93.4 M | 3.18 M | 4.14 M | 2.92 M | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 104 M | 2.92 M | 31.2 M |
Quarterly Total Assets Tenax Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 122 M | 123 M | 103 M | 106 M | 112 M | 96.7 M | 99.8 M | 10.6 M | 14.5 M | 11.7 M | 11.9 M | 14 M | 15.3 M | 3.4 M | 4.74 M | 8.36 M | 3.74 M | 5.99 M | 8.91 M | 2.89 M | 4.56 M | 6.87 M | 6.87 M | 6.87 M | 6.87 M | 6.37 M | 6.37 M | 6.37 M | 6.37 M | 13.3 M | 13.3 M | 13.3 M | 13.3 M | 9.89 M | 9.89 M | 9.89 M | 9.89 M | 23.3 M | 23.3 M | 23.3 M | 23.3 M | 73 M | 73 M | 73 M | 73 M | 33.9 M | 89.2 M | 91.4 M | 93.4 M | 3.04 M | 4.36 M | 5.89 M | 3.18 M | 5.89 M | 3.54 M | 5.13 M | 4.14 M | - | 4.55 M | 6.18 M | 2.92 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 123 M | 2.89 M | 29.5 M |
Total Assets of other stocks in the Biotechnology industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
NuCana plc
NCNA
|
29.8 M | $ 1.03 | 4.54 % | $ 11.6 B |  Britain |
 |
BioVie
BIVI
|
21.6 M | $ 1.33 | 7.26 % | $ 1.96 M |  USA |
 |
CEL-SCI Corporation
CVM
|
28.2 M | $ 1.6 | -1.84 % | $ 12.8 M | USA |
 |
PMV Pharmaceuticals
PMVP
|
117 M | $ 1.15 | -9.84 % | $ 60.4 M | USA |
 |
Cytokinetics, Incorporated
CYTK
|
1.42 B | $ 60.7 | -0.87 % | $ 7.29 M | USA |
 |
Daré Bioscience
DARE
|
32.5 M | $ 0.64 | -0.33 % | $ 7.15 M | USA |
 |
DBV Technologies S.A.
DBVT
|
234 M | $ 9.97 | 2.21 % | $ 1.39 B |  France |
 |
Denali Therapeutics
DNLI
|
1.14 B | $ 18.66 | 1.35 % | $ 3.22 B | USA |
 |
Precision BioSciences
DTIL
|
154 M | $ 6.4 | -3.61 % | $ 82.1 M | USA |
 |
Dyadic International
DYAI
|
9.95 M | $ 0.43 | 7.72 % | $ 15.6 M | USA |
 |
Enlivex Therapeutics Ltd.
ENLV
|
2.33 B | $ 0.16 | -7.21 % | $ 7.31 M |  Israel |
 |
Enanta Pharmaceuticals
ENTA
|
281 M | $ 12.0 | 3.09 % | $ 256 K | USA |
 |
Entera Bio Ltd.
ENTX
|
16 M | $ 2.83 | -3.25 % | $ 131 M | Israel |
 |
Passage Bio
PASG
|
36.5 M | $ 3.36 | -0.33 % | $ 10.8 M | USA |
|
Forte Biosciences
FBRX
|
82.8 M | $ 76.99 | 0.03 % | $ 997 M | USA |
 |
Exelixis
EXEL
|
2.84 B | $ 65.14 | 0.95 % | $ 17.7 B | USA |
|
Immatics N.V.
IMTX
|
562 M | $ 7.16 | -2.12 % | $ 876 M |  Germany |
 |
Aptose Biosciences
APTO
|
10 M | - | -45.71 % | $ 1.2 M |  Canada |
 |
Gilead Sciences
GILD
|
59 B | $ 158.71 | 1.71 % | $ 197 B | USA |
 |
Grifols, S.A.
GRFS
|
21.4 B | $ 7.91 | 4.56 % | $ 5.38 B |  Spain |
 |
GlaxoSmithKline plc
GSK
|
61.1 B | $ 51.12 | 0.73 % | $ 207 B | Britain |
 |
Halozyme Therapeutics
HALO
|
2.53 B | $ 128.07 | 1.94 % | $ 15.3 B | USA |
 |
Bio-Techne Corporation
TECH
|
2.59 B | $ 72.69 | 0.2 % | $ 11.3 B | USA |
 |
Harmony Biosciences Holdings
HRMY
|
1.27 B | $ 36.84 | 1.97 % | $ 2.12 B | USA |
 |
Immuron Limited
IMRN
|
10.1 M | $ 0.96 | 0.25 % | $ 222 M |  Australia |
 |
Immunic
IMUX
|
24.1 M | $ 7.28 | -1.75 % | $ 1.13 B | USA |
 |
Immunovant
IMVT
|
957 M | $ 28.19 | -0.79 % | $ 5.14 B | USA |
 |
INmune Bio
INMB
|
32.4 M | $ 1.43 | -2.05 % | $ 35.4 M | USA |
 |
Insmed Incorporated
INSM
|
2.26 B | $ 93.44 | 0.05 % | $ 18.6 B | USA |
 |
Ionis Pharmaceuticals
IONS
|
3.52 B | $ 43.42 | 1.13 % | $ 6.95 B | USA |
 |
Innate Pharma S.A.
IPHA
|
62.7 M | $ 1.47 | -1.64 % | $ 132 M | France |
 |
Ironwood Pharmaceuticals
IRWD
|
397 M | $ 3.49 | 0.87 % | $ 565 M | USA |
 |
Inventiva S.A.
IVA
|
119 M | $ 3.67 | -1.08 % | $ 219 M | France |
 |
Jazz Pharmaceuticals plc
JAZZ
|
11.7 B | $ 205.67 | -3.89 % | $ 12.5 B |  Irlanda |
 |
Johnson & Johnson
JNJ
|
199 B | $ 266.51 | 1.02 % | $ 642 B | USA |
 |
Kamada Ltd.
KMDA
|
379 M | $ 7.93 | 2.06 % | $ 457 M | Israel |
 |
Krystal Biotech
KRYS
|
1.33 B | $ 313.53 | 0.65 % | $ 9.07 B | USA |
 |
Kura Oncology
KURA
|
738 M | $ 9.64 | 0.31 % | $ 845 M | USA |
 |
Kymera Therapeutics
KYMR
|
1.74 B | $ 114.86 | 3.7 % | $ 9.7 B | USA |
 |
Lineage Cell Therapeutics
LCTX
|
113 M | $ 1.0 | -0.1 % | $ 230 M | USA |
 |
Nanobiotix S.A.
NBTX
|
67.8 M | $ 31.65 | 7.8 % | $ 1.51 T | France |
 |
Longeveron
LGVN
|
10.3 M | $ 1.61 | 0.62 % | $ 28.3 B | USA |
 |
Eli Lilly and Company
LLY
|
112 B | $ 1 277.31 | 0.3 % | $ 1.15 T | USA |
 |
Lipocine
LPCN
|
17 M | $ 1.43 | -0.69 % | $ 7.79 M | USA |
|
Larimar Therapeutics
LRMR
|
146 M | $ 2.22 | -5.53 % | $ 184 M | USA |
 |
vTv Therapeutics
VTVT
|
89.9 M | $ 25.97 | 1.64 % | $ 103 M | USA |
 |
Moleculin Biotech
MBRX
|
22.1 M | $ 6.9 | 6.12 % | $ 8.17 M | USA |
 |
MacroGenics
MGNX
|
257 M | $ 2.17 | -3.56 % | $ 137 M | USA |
 |
Milestone Pharmaceuticals
MIST
|
114 M | $ 0.64 | -0.88 % | $ 68 M | Canada |
 |
Merck & Co.
MRK
|
137 B | $ 140.44 | -3.32 % | $ 351 B | USA |